Chiasma

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

The stock price of Chiasma Inc (NASDAQ: CHMA) increased by over 10% pre-market. This is why it happened.

CHMA Stock Price Increases Over 10% Pre-Market: Why It Happened

--93% of all patients who enrolled as a responder to MYCAPSSA ® maintained their biochemical response at the end of the 48-week open-label extension (OLE) period-- --Safety profile during the OLE was generally consistent with the safety observed in the CHIASMA OPTIMAL trial

Chiasma Presents Long-Term Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly at ENDO 2021

Chiasma Inc (NASDAQ: CHMA) has announced new data from the MPOWERED Phase 3 trial of Mycapssa as the first oral therapy to treat acromegaly. Chiasma presented the data at the Endocrine Society's annual meeting.

Chiasma's Mycapssa Improves Acromegaly Related Symptoms After Switching From iSRLs

--Data supports MYCAPSSA® as non-inferior to long-acting injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related symptoms and patient reported outcomes after switching from iSRLs--

Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021

-- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases currently treated with burdensome and painful injections, as evidenced by its recent approval of MYCAPSSA as the first and only oral therapy for the treatment of acromegaly, today announced that it will be presenting data from two Phase 3 clinical trials: the open-label extension of the CHIASMA OPTIMAL study and the MPOWERED™ study, at the Endocrine Society's annual meeting, ENDO 2021. The conference will be held virtually from March 20-23, 2021.

Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021

Chiasma, Inc. (CHMA) CEO Raj Kannan on Q4 2020 Results - Earnings Call Transcript

Chiasma (CHMA) delivered earnings and revenue surprises of 8.57% and -17.75%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Chiasma (CHMA) Reports Q4 Loss, Lags Revenue Estimates

Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million

Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET

Chiasma to Report Fourth Quarter 2020 Results on March 4

CHMA's MYCAPSSA was approved and launched last year for acromegaly. MYCAPSSA is an oral formulation of a well-known injection.

Chiasma: Undervalued Despite Approval And Market Potential Of MYCAPSSA

Appointment provides extensive commercial-stage public company financial leadership experience Appointment provides extensive commercial-stage public company financial leadership experience

Chiasma Announces Hiring of John Doyle as Chief Financial Officer

MYCAPSSA ® launch in US continuing to gain traction with physicians, patients, and payers

Chiasma Provides Corporate Update and Previews Expected 2021 Milestones

Bausch Health Companies Inc

Paratek Pharma

The Bruce Fund, co-managed by founder Robert Bruce (Trades, Portfolio) and his son Jeff, revealed in November that its top trades included a new position in Chiasma Inc. (NASDAQ:CHMA), position boosts in Paratek Pharmaceuticals Inc. (NASDAQ:PRTK) and Bausch Health Companies Inc. (NYSE:BHC) and reductions in its Apple Inc. (NASDAQ:AAPL) and NextEra Energy Inc. (NYSE:NEE) holdings.

The Bruce Fund's Top 5 3rd-Quarter Trades

Chiasma launched its first product, Mycapssa, on August 31, 2020. Mycapssa is the first product utilizing Chiasma's proprietary technology platform that enables oral version of previously injection-only therapies by transiently enhancing intestinal permeability.

Chiasma Trades At A Big Discount To Fair Value With Mycapssa On The Market

Today, we revisit Chiasma for the first time in over a year. This promising small-cap name recently posted some encouraging trial results and has seen a big recent insider purchase by its CEO.

Revisiting Chiasma

NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be presenting and participating in investor meetings at both the Piper Sandler Healthcare Conference as well as the Evercore ISI HealthCONx Conference. Details for each conference are as follows:

Chiasma to Participate in Two Investor Conferences in December

NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that it will host an expert panel on acromegaly and the results from its recently completed MPOWERED® Phase 3 clinical trial on Monday, November 30, 2020 at 11:00 am Eastern Time.

Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results

91% of patients on MYCAPSSA maintained IGF-1 response in the 9-month randomized , controlled phase of the non-inferiority trial

Chiasma Announces Positive Topline Results from the MPOWERED™ Phase 3 Clinical Trial Comparing MYCAPSSA® (octreotide capsules) to Long Acting Injectables for the Maintenance Treatment of Adults with Acromegaly

NEEDHAM, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injections, today announced that management will be participating in the Jefferies Virtual London Healthcare Conference, which is being held November 17-19. Details of the presentation are as follows:

Chiasma to Participate in the Jefferies Virtual London Healthcare Conference

Chiasma's (CHMA) CEO Raj Kannan on Q3 2020 Results - Earnings Call Transcript

L aunched MYCAPSSA® in U.S. earlier than expected and recognized first net product revenues in September

Chiasma Reports Third Quarter 2020 Results and Provides MYCAPSSA Launch Update

NEEDHAM, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA) today recognizes Acromegaly Awareness Day, which is observed every year on November 1, and reiterates its commitment to people with acromegaly and the patient advocacy groups in their ongoing efforts to increase awareness of acromegaly and support the unique needs of people living with acromegaly.

Chiasma Reinforces Commitment to People with Acromegaly and Advocacy Organizations on Acromegaly Awareness Day

Chiasma to Report Third Quarter 2020 Results on November 5

Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer

Chiasma Announces Planned Transition of Former CEO

NEEDHAM, Mass., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to reduce the burden of chronic injections for people with rare diseases, today announced that management will be participating in two investor conferences in September.

News for Chiasma Stock (CHMA)